Table 2 Changes in various parameters between baseline and 12 weeks after trelagliptin therapy
| Â | Baseline | After 12Â weeks | P value |
|---|---|---|---|
FMD (%), mean (SD) | 2.42 (2.7) | 2.66 (3.8) | 0.785 |
Adiponectin (μg/mL), mean (SD) | 7.72 (6.9) | 8.82 (8.3) | 0.002 |
ADMA (μM/L), mean (SD) | 0.41 (0.0) | 0.40 (0.0) | 0.402 |
BMI (kg/m2), mean (SD) | 24.6 (3.2) | 24.4 (3.0) | 0.219 |
Body weight (kg), mean (SD) | 64.9 (8.9) | 64.5 (9.5) | 0.266 |
HbA1c (%), mean (SD) | 7.5 (1.0) | 7.1 (0.9) | 0.051 |
Fasting plasma glucose, mean (SD) | 145.8 (35.9) | 129.1 (36.4) | 0.033 |
IRI (μU/mL), mean (SD) | 14.3 (10.1) | 14.5 (10.6) | 0.913 |
HOMA index, mean (SD) | 5.0 (4.0) | 4.5 (4.2) | 0.469 |
β-cell function, mean (SD) | 69.0 (48.7) | 88.3 (74.3) | 0.193 |
eGFR (mL/min/1.73Â m2), mean (SD) | 82.7 (21.1) | 79.8 (22.3) | 0.062 |
ACR (mg/gCr), mean (SD) | 39.7 (62.3) | 34.7 (53.6) | 0.244 |
Systolic blood pressure (mmHg), mean (SD) | 129.8 (8.0) | 129.9 (9.6) | 0.945 |
Diastolic blood pressure (mmHg), mean (SD) | 79.7 (7.3) | 77.6 (8.8) | 0.240 |
LDLC (mg/dL), mean (SD) | 120.5 (31.4) | 110.4 (28.7) | 0.001 |
HDLC (mg/dL) mean (SD) | 53.2 (14.0) | 52.9 (12.9) | 0.745 |
TG (mg/dL), mean (SD) | 134.3 (49.4) | 132.6 (54.5) | 0.871 |
Mean CIMT (mm), mean (SD) | 1.76 (1.3) | 1.42 (0.5) | 0.227 |
Mean ba-PWV (cm/s), mean (SD) | 1633 (244.1) | 1569 (217.1) | 0.045 |